Key result
The 2021 AHA/ACC/Multisociety Chest Pain Guideline emphasizes the importance of preventive therapies and anatomical testing for patients with nonobstructive or obstructive coronary artery disease.
The 2021 AHA/ACC chest pain guideline emphasizes preventive therapies and redefines CAD to include nonobstructive plaque, recognizing its associated risk for atherosclerotic events.
A core principle of the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Chest Pain Guideline is the importance of preventive therapies among patients with nonobstructive or obstructive coronary artery disease (CAD). Accordingly, this editorial provides unique insights that emphasize the role of preventive cardiology throughout the new guideline. For the first time, CAD was defined to also include nonobstructive plaque. This definition was based on the fact that individuals who have nonobstructive plaque are at an increased risk of atherosclerotic events compared with those who do not. Herein, we highlight guideline recommendations related to the diagnosis and management of nonobstructive CAD. We also highlight recommendations which emphasize the importance of preventive therapies. Adoption of these recommendations have the potential to lead to enhanced preventive therapies and improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Cardoso et al. (2022) conducted an editorial in Coronary artery disease. The 2021 AHA/ACC/Multisociety Chest Pain Guideline emphasizes the importance of preventive therapies and anatomical testing for patients with nonobstructive or obstructive coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: